BibSonomy publications for /author/AllredFri Feb 05 11:28:39 CET 2010Blood3986-993A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease1052005use toxicity therapy therapeutic response protein inhibitors genetics fms-Like drug cells antagonists analysis Vascular Tyrosine Studies SU11248 Research Receptors Receptor Rate Pyrroles Proto-Oncogene Proteins Protein-Tyrosine Platelet-Derived Pharmacokinetics Myeloid Mutation Middle Metabolic Male Lung Leukemia Kinases Kinase Indoles Hypertension Humans Human Growth Genotype Follow-Up Female Factor Endothelial Clearance Aged Acute 3 & Fifteen patients with refractory AML were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine kinase 3 (Flt3), Kit, vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) receptors. Separate cohorts of patients received SU11248 for 4-week cycles followed by either a 2- or a 1-week rest period. At the starting dose level of 50 mg (n = 13), no dose-limiting toxicities were observed. The most frequent grade 2 toxicities were edema, fatigue, and oral ulcerations. Two fatal bleedings possibly related to the disease, one from a concomitant lung cancer and one cerebral bleeding, were observed. At the 75 mg dose level (n = 2), one case each of grade 4 fatigue, hypertension, and cardiac failure was observed, and this dose level was abandoned. All patients with FLT3 mutations (n = 4) had morphologic or partial responses compared with 2 of 10 evaluable patients with wild-type FLT3. Responses, although longer in patients with mutatedFri Feb 05 11:28:39 CET 2010Blood3986-993A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease1052005use toxicity therapy therapeutic response protein inhibitors genetics fms-Like drug cells antagonists analysis Vascular Tyrosine Studies SU11248 Research Receptors Receptor Rate Pyrroles Proto-Oncogene Proteins Protein-Tyrosine Platelet-Derived Pharmacokinetics Myeloid Mutation Middle Metabolic Male Lung Leukemia Kinases Kinase Indoles Hypertension Humans Human Growth Genotype Follow-Up Female Factor Endothelial Clearance Aged Acute 3 & Fifteen patients with refractory AML were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine kinase 3 (Flt3), Kit, vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) receptors. Separate cohorts of patients received SU11248 for 4-week cycles followed by either a 2- or a 1-week rest period. At the starting dose level of 50 mg (n = 13), no dose-limiting toxicities were observed. The most frequent grade 2 toxicities were edema, fatigue, and oral ulcerations. Two fatal bleedings possibly related to the disease, one from a concomitant lung cancer and one cerebral bleeding, were observed. At the 75 mg dose level (n = 2), one case each of grade 4 fatigue, hypertension, and cardiac failure was observed, and this dose level was abandoned. All patients with FLT3 mutations (n = 4) had morphologic or partial responses compared with 2 of 10 evaluable patients with wild-type FLT3. Responses, although longer in patients with mutatedMon Oct 12 00:00:00 CEST 2009IPDPSconf/ipps/20091-4Smith-Waterman implementation on a FSB-FPGA module using the Intel Accelerator Abstraction Layer.2009dblp Wed Mar 18 00:00:00 CET 2009IAAIconf/iaai/199187-103AGATHA: An Integrated Expert System to Test and Diagnose Complex Personal Computer Boards.1991dblp Thu Jun 26 00:00:00 CEST 2008APGVconf/apgv/2004161ACM International Conference Proceeding SeriesAlgorithms for image database navigation and tuning of object selective neurons in the non-human primate.732004dblp Wed Jun 04 00:00:00 CEST 2008SenSysconf/sensys/2007117-129SensorFlock: an airborne wireless sensor network of micro-air vehicles.2007dblp Sun Mar 02 02:12:02 CET 2008{Compliant Mechanism Suspensions}2003imported Tue Dec 07 00:00:00 CET 2004FCCMconf/fccm/2004324-325An FPGA Implementation for a High Throughput Adaptive Filter Using Distributed Arithmetic.2004dblp Thu Jan 03 00:00:00 CET 2002International Conference on Computational Science (2)conf/iccS/2001-2550-557Lecture Notes in Computer ScienceDistributed Test Capability Using Infrared Scene Projector Technology.20742001dblp